| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 110.00 | 231.10 |
| Pretax Income | -36.40 | 57.60 |
| Net Income | -32.70 | 51.20 |
| Diluted EPS | -0.64 | 0.91 |
- Net Income YoY
- -163.9%
Key highlights
- Quarterly revenue fell to $110.00 million from $231.10 million in the prior year
- Net income declined 163.9% year-over-year to a loss of $32.70 million
- Diluted earnings per share dropped to -$0.64 compared to $0.91 in Q3-2025
- Total assets decreased to $995.2 million from $1,318.6 million at year-end 2025
- The company is operating under a new 2026 Term Loan Agreement to manage debt
How the Period Went
Emergent BioSolutions reported total revenue of $110.00 million for the third quarter of 2026, marking a significant decline from the $231.10 million recorded in the same period last year. This sharp drop in top-line performance directly impacted the bottom line, resulting in a net loss of $32.70 million compared to a net income of $51.20 million in Q3-25. Diluted earnings per share shifted from $0.91 to -$0.64 year-over-year. The 163.9% decrease in net income underscores a challenging quarter as the company navigates shifts in its medical countermeasure contract timing and commercial product distribution cycles.
Margins and Profitability
The company experienced a substantial swing in profitability, with pretax income falling to a loss of $36.40 million from a profit of $57.60 million in the prior year. This margin compression occurred as the company managed significant debt obligations under its 2026 Term Loan Agreement. Total assets also contracted to $995.2 million as of September 30, 2026, down from $1,318.6 million at the end of 2025. Financial stability efforts are currently centered on optimizing the cost structure and addressing satisfied performance obligations, which stood at $268.7 million earlier in the year according to SEC filings.
Business Overview
Emergent BioSolutions operates as a specialty pharmaceutical firm specializing in public health preparedness. The company’s business model is bifurcated between medical countermeasure (MCM) contracts with the U.S. government and commercial healthcare products. Its MCM portfolio includes vaccines and therapeutics targeting biological and chemical threats, while its commercial segment is led by NARCAN Nasal Spray for opioid overdose reversal. By serving both federal defense needs and the generic drug market, the company maintains a unique position at the intersection of national security and public health, though it remains sensitive to government procurement timelines.
Financial Context
In the context of recent performance, the $110.00 million in Q3 revenue represents a sequential decline from $234.3 million in Q2 2026 and $156.1 million in Q1 2026, based on reports from GlobeNewswire and Emergent BioSolutions. With a market capitalization of approximately $330.2 million and a share price of $6.44, the stock has faced an 11.29% decline over the past quarter. The Relative Strength Index of 46.7 suggests the equity is trading in a neutral technical range. Investors are also monitoring the company's $50 million share repurchase program, which remains active until March 2027.
Down 9.8% since our story on 3 Nov: $6.44 when we broke it → $5.81 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $6.36 |
|---|---|
| 20 Oct | $6.29 |
| 21 Oct | $6.20 |
| 22 Oct | $6.23 |
| 23 Oct | $6.23 |
| 26 Oct | $6.34 |
| 27 Oct | $6.67 |
| 28 Oct | $7.09 |
| 29 Oct | $7.22 |
| 30 Oct | $6.81 |
| 2 Nov | $6.44 |
| 3 Nov | $6.25 |
| 4 Nov | $5.90 |
| 5 Nov | $5.85 |
| 6 Nov | $6.06 |
| 9 Nov | $6.10 |
| 10 Nov | $6.05 |
| 11 Nov | $6.04 |
| 12 Nov | $5.89 |
| 13 Nov | $5.79 |
| 16 Nov | $5.81 |
Industry Landscape
The specialty drug manufacturing sector is currently navigating a period of stabilization following post-pandemic demand shifts. Peers such as SIGA Technologies and Bavarian Nordic, which also provide biodefense solutions, face similar lumpy revenue patterns dictated by government stockpiling cycles. Within the broader healthcare sector, Emergent’s transition is marked by executive changes, including the upcoming retirement of CFO Richard S. Lindahl in December 2026, according to StockTitan. As the industry shifts toward more resilient supply chains, Emergent’s focus on the 2026 Term Loan Agreement and its medical countermeasure pipeline remains critical for competitive positioning against generic manufacturers.
| Date | Announcement | Amount |
|---|---|---|
| 02 Nov 2026 | Q3 2026 total revenuesSource: stocktitan.net | $110.0 Million |
| 05 Aug 2026 | Q2 2026 total revenuesSource: globenewswire.com | $234.3 Million |
| 30 Apr 2026 | Q1 2026 total revenuesSource: investors.emergentbiosolutions.com | $156.1 Million |
| 26 Feb 2026 | Q4 2025 total revenuesSource: SEC filing | $148.7 Million |
| 29 Oct 2025 | Q3 2025 total revenuesSource: investors.emergentbiosolutions.com | $231.1 Million |
| 06 Aug 2025 | Q2 2025 total revenuesSource: biospace.com | $140.9 Million |
| Share price | $6.44 |
|---|---|
| Market cap | $330M |
| Revenue (annual) | $705M |
| 1-month price change | +1.10% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Emergent BioSolutions Inc. announcing its third quarter 2026 financial results.
Track Emergent BioSolutions Inc. live
Get the next Emergent BioSolutions Inc. SEC filing seconds after it lands.



